Aurinia Lifts Revenue on LUPKYNIS Growth, Sets Strong 2026 Sales Outlook
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aurinia Pharmaceuticals ( (AUPH) ) just unveiled an announcement.
Aurinia Pharmaceuticals reported strong 2025 results, with total revenue rising 20% to $283.1 million and fourth-quarter revenue up 29% to $77.1 million versus 2024. Net product sales of its flagship lupus nephritis drug LUPKYNIS grew 25% for the full year to $271.3 million, underscoring the drug’s central role in the company’s growth.
The company also issued 2026 sales guidance for LUPKYNIS of $305 million to $315 million, signaling expectations of continued double-digit expansion in its core franchise. The updated outlook and sustained revenue momentum highlight Aurinia’s strengthening position in the lupus nephritis market and provide investors with increased visibility into the company’s near-term growth trajectory.
The most recent analyst rating on (AUPH) stock is a Buy with a $16.50 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.
Spark’s Take on AUPH Stock
According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.
Aurinia Pharmaceuticals’ strong financial performance and positive earnings call are the most significant factors driving the stock’s score. The company’s robust revenue growth, profitability improvements, and promising clinical developments are key strengths. However, technical indicators suggest the stock may be overbought, and its high P/E ratio indicates a premium valuation, which could limit further upside.
To see Spark’s full report on AUPH stock, click here.
More about Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc., based in Canada with operations in Maryland and Alberta, is a biopharmaceutical company listed on Nasdaq under the ticker AUPH. Its primary commercial product is LUPKYNIS, the first FDA-approved oral therapy for adult patients with active lupus nephritis, targeting the autoimmune and renal disease market.
Average Trading Volume: 1,044,377
Technical Sentiment Signal: Buy
Current Market Cap: $1.92B
See more data about AUPH stock on TipRanks’ Stock Analysis page.
